Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Star Combo Pharma Ltd. ( (AU:S66) ).
Star Combo Pharma Ltd. has released its Appendix 4D half-year report for the six months ended 31 December 2025, covering the group’s financial statements, directors’ report, and auditor reviews. The publication of this statutory report provides investors and stakeholders with updated visibility on the company’s interim financial performance and governance, although detailed operational or earnings information is not disclosed in the brief release excerpt provided.
The most recent analyst rating on (AU:S66) stock is a Buy with a A$0.23 price target. To see the full list of analyst forecasts on Star Combo Pharma Ltd. stock, see the AU:S66 Stock Forecast page.
More about Star Combo Pharma Ltd.
Star Combo Pharma Ltd. is an Australia-based pharmaceutical and healthcare company listed on the ASX under the ticker S66. The group operates through Star Combo Pharma Ltd. and its controlled entities, focusing on the manufacture and sale of health-related products in the domestic market and potentially abroad, as indicated by its consolidated reporting structure.
Average Trading Volume: 20,405
Technical Sentiment Signal: Hold
Current Market Cap: A$25.65M
For detailed information about S66 stock, go to TipRanks’ Stock Analysis page.